ERAS Erasca Inc: רווח למניה לשנה מתגלגלת

The market trend visualized in monetary format on GURU.Markets shows the EPS of Erasca, Inc. (ERAS) at -110.20. The market is currently awaiting the results of phase two trials for melanoma drugs, while R&D costs still exceed revenues. The business focuses on developing targeted therapies to block RAS/MAPK pathways, seeking collaborations with industry behemoths. The team consists of leading biologists motivated by stock options.

This indicator captures the percentage change in earnings per share over a rolling twelve-month period. It allows for an assessment of the scaling rate of profitability, preventing the erroneous extrapolation of temporary peaks. By analyzing the year-over-year EPS trend (over 12 months), an investor determines the sustainability of the business. For Erasca, Inc. (ERAS), such volatility reflects the costs of implementing green synthesis and ethical compliance in oncology.